dm+d

Unassigned

New Medicines

Acute bacterial skin and skin structure infections (ABSSI)

Information

New molecular entity
Not Known
Innovation Pharmaceuticals

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

First-in-class a synthetic, defensin-mimetic. Directly lyses the bacterial cell membrane by penetrating into it and disrupting the barrier and membrane-associated metabolic functions, leading to bacterial death.
In England in 2019/20, there were ~250,000 finished consultant episodes of skin infections including cellulitis, local infections of skin tissues and cutaneous abscess. This would be reserved for resistant skin infections; 6% on average. Therefore, ~15,000 people could be eligible for this in England (~25 per 100,000 people). [15]
Acute bacterial skin and skin structure infections (ABSSI)
Intravenous